Use of Hypolipidemic Drugs and the Risk of Second Primary
Malignancy in Colorectal Cancer Patients

J 2022

Use of Hypolipidemic Drugs and the Risk of Second Primary Malignancy in Colorectal Cancer Patients

HALÁMKOVÁ, Jana, Lucia BOHOVICOVÁ, Lucie PEHALOVÁ, Roman GONĚC, Teodor STANĚK et. al.

Basic information

Original name

Use of Hypolipidemic Drugs and the Risk of Second Primary Malignancy in Colorectal Cancer Patients

Authors

HALÁMKOVÁ, Jana (203 Czech Republic, belonging to the institution), Lucia BOHOVICOVÁ (203 Czech Republic, belonging to the institution), Lucie PEHALOVÁ (203 Czech Republic, belonging to the institution), Roman GONĚC (203 Czech Republic), Teodor STANĚK (203 Czech Republic, belonging to the institution), Tomáš KAZDA (203 Czech Republic, belonging to the institution), Lucie MOUKOVÁ (203 Czech Republic), Dagmar ADÁMKOVÁ KRÁKOROVÁ (203 Czech Republic), Šárka KOZÁKOVÁ (203 Czech Republic, belonging to the institution), Marek SVOBODA (203 Czech Republic, belonging to the institution), Regina DEMLOVÁ (203 Czech Republic, guarantor, belonging to the institution) and Igor KISS (203 Czech Republic, belonging to the institution)

Edition

Cancers, BASEL, MDPI, 2022, 2072-6694

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30204 Oncology

Country of publisher

Switzerland

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 5.200

RIV identification code

RIV/00216224:14110/22:00125614

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.3390/cancers14071699

UT WoS

000781330800001

Keywords in English

hypolipidemic agents; statins; second primary malignancies; second primary cancers; multiple primary neoplasms; colorectal cancer; cancer survivors

Abstract

V originále

Simple Summary Hypolipidemic drugs are among the most frequently prescribed medications in the Western world. Since many studies have indicated their role in carcinogenesis, this work aimed to investigate their association with the occurrence of a second primary malignancy in colorectal cancer survivors. The overall incidence of a second neoplasm was not linked to hypolipidemic medication; however, a subgroup analysis revealed a lower incidence of secondary neoplasia in statin users. When stratified by cancer types, a significant increase in gastric and bladder cancer was detected among colorectal cancer patients using hypolipidemic drugs. Survival outcomes in patients with early-stage colorectal carcinoma who suffered second cancer were significantly worse if treated with hypolipidemic drugs. Although our results do not provide evidence for a causative relationship between hypolipidemic medication and carcinogenesis, these correlations might steer the direction of tertiary prevention care towards specific risk factors shared between cardiovascular diseases and cancer. An increasing number of studies has brought evidence of the protective role of statin use against different types of cancer. However, data on their association with second primary malignancies (SPMs) are lacking. The purpose of this study was to determine the role of hypolipidemic treatment in the prevention of second primary cancer in colorectal cancer (CRC) survivors. We conducted a retrospective single-institution study of 1401 patients with newly diagnosed colorectal cancer from January 2003 to December 2016, with follow-up until December 2020. An SPM was detected in 301 patients (21%), and the incidence was significantly lower in patients with statin medication. However, stratification by cancer types revealed an increased incidence of bladder and gastric cancer in hypolipidemic users. A Kaplan-Meier analysis of early-stage CRC survivors with an SPM showed a significant survival benefit in patients without a history of hypolipidemic treatment. Despite the protective role of statins on overall second cancer incidence, these data indicate that CRC survivors treated with hypolipidemic drugs should be screened more cautiously for SPMs, especially for gastric and bladder cancer.

Links

NU21-09-00558, research and development project

Name: Vliv řízené pohybové aktivity na dysbalanci autonomního nervového systému, imunitního systému a sníženou zdravotní zdatnost u onkologických pacientů po adjuvantní chemoterapii.

Investor: Ministry of Health of the CR, Subprogram 1 - standard

90125, large research infrastructures

Name: BBMRI-CZ III

90128, large research infrastructures

Name: CZECRIN III

Citovat

HALÁMKOVÁ, Jana, Lucia BOHOVICOVÁ, Lucie PEHALOVÁ, Roman GONĚC, Teodor STANĚK, Tomáš KAZDA, Lucie MOUKOVÁ, Dagmar ADÁMKOVÁ KRÁKOROVÁ, Šárka KOZÁKOVÁ, Marek SVOBODA, Regina DEMLOVÁ and Igor KISS. Use of Hypolipidemic Drugs and the Risk of Second Primary Malignancy in Colorectal Cancer Patients. Cancers. BASEL: MDPI, 2022, vol. 14, No 7, p. 1-13. ISSN 2072-6694. Available from: https://dx.doi.org/10.3390/cancers14071699.

@article{1845077,
   author = {Halámková, Jana and Bohovicová, Lucia and Pehalová, Lucie and Goněc, Roman and Staněk, Teodor and Kazda, Tomáš and Mouková, Lucie and Adámková Krákorová, Dagmar and Kozáková, Šárka and Svoboda, Marek and Demlová, Regina and Kiss, Igor},
   article_location = {BASEL},
   article_number = {7},
   doi = {http://dx.doi.org/10.3390/cancers14071699},
   keywords = {hypolipidemic agents; statins; second primary malignancies; second primary cancers; multiple primary neoplasms; colorectal cancer; cancer survivors},
   language = {eng},
   issn = {2072-6694},
   journal = {Cancers},
   title = {Use of Hypolipidemic Drugs and the Risk of Second Primary Malignancy in Colorectal Cancer Patients},
   url = {https://www.mdpi.com/2072-6694/14/7/1699},
   volume = {14},
   year = {2022}
}

TY  - JOUR
ID  - 1845077
AU  - Halámková, Jana - Bohovicová, Lucia - Pehalová, Lucie - Goněc, Roman - Staněk, Teodor - Kazda, Tomáš - Mouková, Lucie - Adámková Krákorová, Dagmar - Kozáková, Šárka - Svoboda, Marek - Demlová, Regina - Kiss, Igor
PY  - 2022
TI  - Use of Hypolipidemic Drugs and the Risk of Second Primary Malignancy in Colorectal Cancer Patients
JF  - Cancers
VL  - 14
IS  - 7
SP  - 1-13
EP  - 1-13
PB  - MDPI
SN  - 20726694
KW  - hypolipidemic agents
KW  - statins
KW  - second primary malignancies
KW  - second primary cancers
KW  - multiple primary neoplasms
KW  - colorectal cancer
KW  - cancer survivors
UR  - https://www.mdpi.com/2072-6694/14/7/1699
N2  - Simple Summary Hypolipidemic drugs are among the most frequently prescribed medications in the Western world. Since many studies have indicated their role in carcinogenesis, this work aimed to investigate their association with the occurrence of a second primary malignancy in colorectal cancer survivors. The overall incidence of a second neoplasm was not linked to hypolipidemic medication; however, a subgroup analysis revealed a lower incidence of secondary neoplasia in statin users. When stratified by cancer types, a significant increase in gastric and bladder cancer was detected among colorectal cancer patients using hypolipidemic drugs. Survival outcomes in patients with early-stage colorectal carcinoma who suffered second cancer were significantly worse if treated with hypolipidemic drugs. Although our results do not provide evidence for a causative relationship between hypolipidemic medication and carcinogenesis, these correlations might steer the direction of tertiary prevention care towards specific risk factors shared between cardiovascular diseases and cancer. An increasing number of studies has brought evidence of the protective role of statin use against different types of cancer. However, data on their association with second primary malignancies (SPMs) are lacking. The purpose of this study was to determine the role of hypolipidemic treatment in the prevention of second primary cancer in colorectal cancer (CRC) survivors. We conducted a retrospective single-institution study of 1401 patients with newly diagnosed colorectal cancer from January 2003 to December 2016, with follow-up until December 2020. An SPM was detected in 301 patients (21%), and the incidence was significantly lower in patients with statin medication. However, stratification by cancer types revealed an increased incidence of bladder and gastric cancer in hypolipidemic users. A Kaplan-Meier analysis of early-stage CRC survivors with an SPM showed a significant survival benefit in patients without a history of hypolipidemic treatment. Despite the protective role of statins on overall second cancer incidence, these data indicate that CRC survivors treated with hypolipidemic drugs should be screened more cautiously for SPMs, especially for gastric and bladder cancer.
ER  -

HALÁMKOVÁ, Jana, Lucia BOHOVICOVÁ, Lucie PEHALOVÁ, Roman GONĚC, Teodor STANĚK, Tomáš KAZDA, Lucie MOUKOVÁ, Dagmar ADÁMKOVÁ KRÁKOROVÁ, Šárka KOZÁKOVÁ, Marek SVOBODA, Regina DEMLOVÁ and Igor KISS. Use of Hypolipidemic Drugs and the Risk of Second Primary Malignancy in Colorectal Cancer Patients. \textit{Cancers}. BASEL: MDPI, 2022, vol.~14, No~7, p.~1-13. ISSN~2072-6694. Available from: https://dx.doi.org/10.3390/cancers14071699.

Detailed Information on Publication Record